Student Access Program Survey

1.Student Name (optional):

2.School Name:

3.Who was your OraPharma Educator?

Other (please specify)

5.Having learned about ARESTIN^®, do you feel that it may be an important part of periodontal treatment for adult patients with pockets ≥5 mm?

4.1. Yes

4.2. No

4.3. Not sure

6.Will you recommend ARESTIN^® for your appropriate periodontal patients once you are a practicing dental healthcare professional?

5.1. Yes

5.2. No

5.3. Not sure

7.Was the course content consistent with the course objective?

6.1. Yes

6.2. No

6.3. Not sure

8.Was the instructor knowledgeable of the subject matter?

7.1. Yes

7.2. No

7.3. Not sure

9.Did the instructor’s presentation improve your understanding of a locally applied antibiotic (LAA)?

8.1. Yes

8.2. No

8.3. Not sure

10.Was there an appropriate amount of time allowed to cover the course materials?

9.1. Yes

9.2. No

9.3. Not sure

11.What part of the course did you find the most useful/interesting?

12.Did the hands-on portion of the presentation prepare you for using ARESTIN^® with your patients?

11.1. Yes

11.2. No

11.3. Not sure

INDICATION
ARESTIN^® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN^® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN^® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN^®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

For Full Prescribing Information or to learn more about the role of ARESTIN^®, visit ArestinProfessional.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

ARESTIN^® is a registered trademark of OraPharma, Inc.

©OraPharma, Inc. 2012 A-1483-12 12/12